Open Access<p>Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus</p>
Author(s) -
Eugene Han,
Minyoung Lee,
Yong-Ho Lee,
Hye Soon Kim,
Byung Wan Lee,
Bong Soo,
Eun Seok Kang
Publication year - 2020
Publication title -
diabetes, metabolic syndrome and obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.853
H-Index - 43
ISSN - 1178-7007
DOI - 10.2147/dmso.s267994
Subject(s) - linagliptin , medicine , dipeptidyl peptidase 4 inhibitor , glycemic , glycated hemoglobin , type 2 diabetes , renal function , diabetes mellitus , type 2 diabetes mellitus , gastroenterology , postprandial , endocrinology , dipeptidyl peptidase 4 , pharmacology , urology
Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely prescribed for type 2 diabetes (T2D) and their glycemic control effects are well studied. However, information regarding the effects of switching DPP-4 inhibitors is limited, especially in older patients.